Sage, Shionogi to collaborate on MDD drug in three Asian countries
Sage Therapeutics and Shionogi & Co. have agreed to collaborate for the clinical development and commercialization of the former’s SAGE-217 for the treatment of major depressive disorder (MDD) and other indications in Japan, Taiwan and South Korea.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.